Jeffrey Rumbyrt, MD
Allergy & Immunology · Lakewood, CONPI 1295735694
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Biocryst US Sales Co., LLC at 26.2% of the total. 2025 is the largest year on record at $77,936, 2.5 times the $31,035 reported in 2019. Among allergy & immunology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 692 payments — averaging $503.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biocryst US Sales Co., LLC$91K
- Takeda Pharmaceuticals U.S.A., Inc.$76K
- Pharming Healthcare, Inc.$67K
- Shire North American Group Inc$25K
- AstraZeneca$18K
- AbbVie$12K
- plus $58K from 24 others
Across 402 payments — averaging $6106.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$578K
- AstraZeneca$451K
- Bristol Myers Squibb$420K
- Sanofi US Services Inc.$387K
- GSK$216K
- Teva Pharmaceuticals USA, Inc.$121K
- plus $283K from 6 others
What the payments were for
- Consulting fees$111,68832%
- Speaking & faculty fees$189,57454%
- Travel & lodging$33,90110%
- Food & beverage$12,8274%
- Education$850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biocryst US Sales Co., LLC | 111 | $91,051 |
| Takeda Pharmaceuticals U.S.A., Inc. | 122 | $76,380 |
| Pharming Healthcare, Inc. | 102 | $67,057 |
| Shire North American Group Inc | 39 | $25,399 |
| AstraZeneca | 63 | $18,201 |
| AbbVie | 25 | $11,766 |
| CSL Behring | 42 | $11,748 |
| Ionis Pharmaceuticals, Inc. | 14 | $9,662 |
| Grifols USA, LLC | 21 | $8,021 |
| Genentech, Inc. | 8 | $5,820 |
| Dermavant Sciences, Inc. | 5 | $4,553 |
| Biocryst Pharmaceuticals, Inc. | 5 | $3,498 |
| Cycle Pharmaceuticals Inc | 8 | $3,120 |
| Regeneron | 2 | $2,944 |
| Genentech USA, Inc. | 22 | $2,159 |
| Amgen | 3 | $1,993 |
| Boehringer Ingelheim | 2 | $1,296 |
| Adare Pharmaceuticals, Inc. | 6 | $1,104 |
| Optinose US, Inc. | 3 | $842 |
| GSK | 26 | $445 |
| Novartis | 19 | $308 |
| Regeneron Healthcare Solutions, Inc. | 17 | $234 |
| Sanofi | 10 | $178 |
| Teva Pharmaceuticals USA, Inc. | 6 | $108 |
| Organon | 4 | $46 |
| Blueprint Medicines Corporation | 2 | $40 |
| Galderma Laboratories, L.p. | 2 | $32 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $26 |
| LEO Pharma Inc. | 1 | $25 |
| Pfizer | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$348,075 in reported general payments places this provider in the 95th percentile of 89 allergy & immunology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 38 | $144,289 |
| Dupixent PenDupilumab | 28 | $115,313 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $19,854 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $13,610 |
| Qvar RedihalerBeclomethasone Dipropionate | 33 | $12,705 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $12,624 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 41 | $8,775 |
| Advair DiskusFluticasone Propion/Salmeterol | 21 | $7,385 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $5,966 |
| Arnuity ElliptaFluticasone Furoate | 20 | $5,385 |
| DuleraMometasone/Formoterol | 11 | $5,066 |
| Epinephrine | 17 | $3,945 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 88 | $3,005 |
| Fluticasone-Salmeterol HfaFluticasone Propion/Salmeterol | 11 | $2,729 |
| Fluticasone Propionate | 23 | $2,409 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $445 | $38,85079 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $108 | $12,70533 claims |
| AstraZenecaSymbicort | $18,201 | $12,62426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 89 allergy & immunology providers in Colorado.
Other allergy & immunology in Lakewood
- Nicole BarberisLakewood$351K
- Paul SchkadeLakewood$52K
- Shikha GuptaLakewood$12K
- Ross PalisLakewood$6K
- Kara CrosbyLakewood$3K
- Jagadish BoggavarapuLakewood$3K
- Rohit KatialDenver$758K
- Christopher WebberColorado Springs$350K
- Eric CaplanColorado Springs$290K
- Eileen WangDenver$274K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.